Latest Commercialisation News

Memphasys Limited has extended the repayment terms of its convertible notes with major shareholder Peters Investments to mid-2026, reinforcing financial flexibility amid ongoing commercial progress.

Papyrus Australia has taken a significant step towards commercialisation by signing a $4.2 million supply contract with TBS Mining Solutions for its biodegradable Collar Keeper® products, while advancing its Adelaide R&D facility.

Simble Solutions has acquired exclusive rights to a cutting-edge 3D zinc oxide nanosensor technology and completed a $2.5 million placement, positioning itself to expand its IoT platform into new safety and environmental monitoring markets.

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.

Proteomics International Laboratories has achieved the prestigious CAP accreditation for its US lab and installed a new mass spectrometry platform, setting the stage for the 2026 launch of its Promarker diagnostic tests in America.

Audio Pixels has successfully developed an independent MEMS fabrication process for its second-generation digital loudspeaker, overcoming previous manufacturing hurdles and paving the way for scalable production.

Environmental Clean Technologies Limited has completed its acquisition of Terrajoule Pty Ltd, securing exclusive rights to innovative soil remediation technology, while raising $3.25 million to fuel its growth and advancing promising fertiliser trials.

Elixir Energy has been granted a 15-year retention license over its entire ATP2044 permit in Queensland’s Taroom Trough, securing 1,362 BCFe of 2C Contingent Gas Resources confirmed by the Daydream-2 well.

Carnegie Clean Energy’s Spanish subsidiary has sold its 2025 Basque R&D tax deductions for €773,163, securing immediate funding to advance its ocean wave energy technology under the ACHIEVE Programme.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.

Adisyn Ltd has completed a strategic review, deciding to boost investment in its graphene-based semiconductor arm while exploring options to unlock value from its managed IT services business.

Central Petroleum has secured strategic interests in the Cooper and Otway Basins through binding agreements with ADX Energy, setting the stage for a multi-million dollar expansion and planned drilling campaigns in 2026 and 2027.